Diseases at the crossroads: Chronic myelogenous leukemia and tuberculosis

Vishal Bhatnagar, Akintoye Adelakun, Trisha Kendall, Noa Holtzman, Maham Farshidpour, Brandi Stevenson, Qing Chen, Ashkan Emadi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Chronic myelogenous leukemia (CML) and tuberculosis (TB) are diseases with effective available therapy. Treating patients who are afflicted simultaneously with both of these conditions is challenging due to significant drug interactions and the requirement of strict adherence to the multi-agent treatment regimen. Here, we report a case of peritoneal tuberculosis which was successfully treated with a non-rifampin based regimen in tandem with ongoing administration of a tyrosine kinase inhibitor, dasatinib, for CML. Wfe discuss treatment challenges and the strategy on how to circumvent them. As prevalence of CML increases worldwide, patients with concomitant CML and TB will be seen more often by physicians in all continents, and development of guidelines on simultaneous management of these conditions is imperative.

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalArchives of Iranian Medicine
Issue number1
StatePublished - Jan 1 2015


  • Chronic myelogenous leukemia (CML)
  • Disease
  • Tuberculosis (TB)

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Diseases at the crossroads: Chronic myelogenous leukemia and tuberculosis'. Together they form a unique fingerprint.

Cite this